5-Amino-1MQ
Small-molecule inhibitor of nicotinamide N-methyltransferase studied in rodent models of energy expenditure, fat oxidation, and adiposity; it is not a peptide.
Overview
5-Amino-1MQ is a small-molecule research compound rather than a peptide. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and related pyridines using S-adenosylmethionine (SAM) as the methyl donor. NNMT activity in white adipose tissue and liver has been studied as a determinant of energy metabolism and adiposity.
Published work has been conducted mainly in cell culture and mouse models, where NNMT inhibition or knockdown has been associated with increased energy expenditure, greater fat oxidation, and resistance to diet-induced obesity. No human clinical data for 5-Amino-1MQ have been published.
Mechanism
The leading hypothesis is that NNMT consumes a substantial pool of SAM in adipose tissue; by blocking this consumption, 5-Amino-1MQ is proposed to preserve cellular methylation capacity, which in turn is thought to shift metabolic gene expression toward increased energy use and fat oxidation.
Alternative and complementary explanations, including effects on nicotinamide handling and NAD+ metabolism, continue to be discussed in the literature. Because the enzyme is expressed in several tissues, the systemic consequences of pharmacological inhibition are not fully characterized.
Dosing
Dosing information is limited to preclinical research; human dosing has not been established. All amounts below reflect published laboratory protocols, not human recommendations.
- In published rodent studies the compound is given orally, typically by gavage or admixed with diet, at amounts scaled to body weight
- In vitro studies use micromolar-range concentrations to inhibit NNMT activity
- Regimens differ between laboratories, and no standardized protocol exists
Expected Effects
- Increased energy expenditure and fat oxidation reported in some mouse studies
- Reduced white adipose tissue mass and markers of adiposity in diet-induced obesity models
- Improved glucose tolerance reported in some NNMT loss-of-function studies
- Findings are preclinical and have not been confirmed in humans
Side Effects & Tolerability
Tolerability data come only from short-term animal studies, in which the compound was generally well tolerated. Human safety, pharmacokinetics, and long-term effects are unknown; because NNMT is expressed in multiple tissues, systemic inhibition could have effects beyond adipose tissue.
Storage
Store the dry powder cool, desiccated, and protected from light and moisture, per supplier instructions. Prepared solutions should follow the manufacturer's recommended solvent and stability window.